NCT06524544Toboroz3. fázis
A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitecan-hziy Versus Standard of Care in the Treatment of Advanced Urothelial Cancer
A Phase III Randomized Trial of Pembrolizumab in Combination With Sacituzumab Govitecan-hziy vs Standard of Care in Anti-PD(L)1-Resistant Advanced Urothelial Cancer
Forrás: ClinicalTrials.gov · Utoljára frissítve: 2026. nov. 4.
Rövid összefoglaló (regiszter, angolul)
This phase III trial compares the effectiveness of pembrolizumab and sacituzumab govitecan-hziy to standard of care in treating patients with urothelial cancer that has spread to nearby tissue or lymph nodes (locally advanced) or that has spread to other places in the body (metastatic). Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Sacituzumab govitecan-hziy is a monoclonal antibody, called sacituzumab, linked to a chemotherapy drug called govitecan-hziy. Sacituzumab attaches to TROP2 positive tumor cells in a targeted way and delivers govitecan-hziy to kill them. The usual treatment approach is treatment with chemotherapy such as cisplatin, carboplatin, gemcitabine, docetaxel or paclitaxel. Cisplatin is in a class of medications known as platinum-containing compounds. It works by killing, stopping or slowing the growth of tumor cells. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of tumor cells. Gemcitabine is a chemotherapy drug that blocks the cells from making deoxyribonucleic acid and may kill tumor cells. Docetaxel is in a class of medications called taxanes. It stops tumor cells from growing and dividing and may kill them. Paclitaxel is in a class of medications called antimicrotubule agents. It stops tumor cells from growing and dividing and may kill them. Giving pembrolizumab and sacituzumab govitecan-hziy may be more effective than usual care of carboplatin or cisplatin with gemcitabine, docetaxel or paclitaxel in treating patients with locally advanced or metastatic urothelial cancer.
- Állapot (regiszter)
- Toboroz
- Fázis (regiszter)
- 3. fázis
- Vizsgálattípus
- Beavatkozással járó
- Résztvevők száma
- 320 (tervezett)
- Első benyújtás
- 2024. júl. 26.
- Kezdés
- 2025. dec. 2.
- Elsődleges befejezés
- 2030. dec. 31.
- Fő szponzor
- National Cancer Institute (NCI)
- Betegségek
- Hólyagrák
- NCT-szám
- NCT06524544
Mit vállalsz
- Vizsgálat típusa: Beavatkozással járó · 3. fázis
- Tervezett résztvevők: 320
- 2025. dec. 2. és az elsődleges befejezés (2030. dec. 31.) között
- 163 helyszín, 1 országban
- Vizitek és vizsgálatok: kérdezd a vizsgálat csapatát, a regiszter nem sorolja fel őket
A(z) ClinicalTrials.gov regisztermezőiből összeállítva. A vizsgálat felépítését írja le.
Ki nem vehet részt
Szó szerint a(z) ClinicalTrials.gov forrásból, témák szerint csoportosítva. Hogy ki vehet részt, azt csak a vizsgálat csapata dönti el.
Kiket keres a vizsgálat
- Patient must be ≥ 18 years of age
- Patient must have Eastern Cooperative Oncology Group (ECOG) performance status 0-2.
- Patient must have locally advanced (unresectable and/or not amenable to curative intent therapy) or metastatic urothelial cancer
- Patient must have histologically (or based on urine cytology) proven conventional urothelial carcinoma (UC) of any urinary tract origin [any histologic subtype except neuroendocrine (small or large cell)] are permitted so long as tumors include ≥ 1% conventional urothelial histology). NOTE: Pure non-urothelial histology is excluded
- Patient must have measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria. Baseline imaging must be obtained ≤ 35 days prior to randomization
- Patient must have the following prior treatment(s). Patient must have had progression on or after the immediate prior anti-cancer therapy
- Patient must have had prior exposure to anti-PD(L)1 therapy [anti -PD(L)1 monotherapy or as a combination regimen in any disease/therapy setting for UC]. Patients must have received at least 1 dose of anti-PD(L)1 therapy
- NOTE: Anti-PD(L)1 therapy does not need to be the most recent therapy received prior to enrollment on this protocol
- NOTE: Patient must not have had progression within 12 weeks of starting their first anti-PD(L) 1 therapy, even if anti-PD-(L)1 treatment was given in more than one lines of therapy
- Patient must have had ≥ 1 line of systemic therapy given in the advanced/metastatic disease setting, except for patients who had received anti-PD(L)1 + enfortumab vedotin in the localized disease setting (e.g., neoadjuvant and/or adjuvant) and had cancer progression within 12 months from the last systemic therapy dose
- For tumors with known FGFR3+ susceptible alteration (for FGFR inhibitor), patients must have received a prior FGFR inhibitor unless contraindicated per physician discretion
- Patient must have received prior enfortumab vedotin or any other Nectin-4 directed therapy or other MMAE-containing therapy in any disease/therapy setting unless contraindicated per physician
- Patient must have had no prior exposure to Sacituzumab govitecan-hziy or other TROP-2 directed therapies or antibody-drug conjugate that contains topo-isomerase I inhibitor, e.g. trastuzumab deruxtecan
- Patient must have Bellmunt score of 0-2. The Bellmunt score assesses a patient's risk and is calculated based on ECOG PS, hemoglobin level and presence of liver metastases
- Patient must not have history of grade 3-4 immune-related adverse events on prior anti-PD1/L1, except for endocrinopathies on adequate hormone therapy repletion and/or clinically insignificant laboratory abnormalities
- Patient must have recovered (i.e., ≤ grade 1) from clinically significant AEs due to previously administered systemic therapy agent, except for endocrinopathies on adequate hormone therapy repletion
- NOTE: Patients with ≤ grade 2 neuropathy, any grade of alopecia, or any grade of non-clinically significant laboratory abnormality are exceptions to this criterion and are allowed in this trial.
- Examples of non-clinically significant laboratory abnormalities include, but are not limited to:
- Lymphopenia or monopenia
- Lymphocytosis or monocytosis
- Increase in amylase or lipase with no clinical correlation
- Any other abnormal laboratory findings that have no clinical relevance per the treating investigator.
- NOTE: If patient has undergone major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to randomization
- Patient must not be pregnant or breast-feeding due to the potential harm to an unborn fetus and possible risk for adverse events in nursing infants with the treatment regimens being used. All patients of childbearing potential must have a blood test or urine study within 14 days prior to randomization to rule out pregnancy. A patient of childbearing potential is defined as anyone, regardless of whether they have undergone tubal ligation, who meets the following criteria: 1) has achieved menarche at some point, 2) has not undergone a hysterectomy or bilateral oophorectomy; or 3) has not been naturally postmenopausal (amenorrhea following cancer therapy does not rule out childbearing potential) for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months). Patient must not nurse infants while on protocol treatment and for 4 months after the last dose of protocol treatment
- Patient must not expect to conceive or father children by using an accepted and effective method(s) of contraception or by abstaining from sexual intercourse for the duration of their participation in the study. Patients of childbearing potential must continue contraceptive method(s) or abstain for 6 months after the last dose of protocol treatment. Patients with partners who could become pregnant should use effective contraception during therapy and for 3 months after the last dose of protocol treatment
- Patient must have the ability to understand and the willingness to sign a written informed consent document. Patients with impaired decision-making capacity (IDMC) who have a legally authorized representative (LAR) or caregiver and/or family member available will also be considered eligible
- Absolute neutrophil count (ANC) ≥ 1,500/uL (obtained ≤ 14 days prior to randomization)
- Platelets ≥ 100,000/uL (obtained ≤ 14 days prior to randomization)
- Albumin ≥ 3 g/dL (obtained ≤ 14 days prior to randomization)
- Total bilirubin ≤ 1.5 x institutional upper limit of normal (ULN) (obtained ≤ 14 days prior to randomization)
- Aspartate aminotransferase (AST)(serum glutamic oxaloacetic transaminase [SGOT]) and alanine aminotransferase (ALT)(serum glutamic pyruvic transaminase [SGPT]) ≤ 3 × institutional ULN or ≤ 5.0 x institutional ULN if known liver metastases (obtained ≤ 14 days prior to randomization)
- Creatinine clearance (CrCl) ≥ 30 mL/min (obtained ≤ 14 days prior to randomization) NOTE: CrCl is estimated using the Cockcroft-Gault formula (or can be measured by 24-hour urine collection if needed)
- Hemoglobin (Hb) ≥ 8.5 g/dl (obtained ≤ 14 days prior to randomization)
- Patient must not have a known genetic UGT1A1 *28/*28 or *6/*6 homozygous variant genotype. Patients with homozygous variant types are considered poor metabolizers and are at higher risk for severe adverse events when compared to wild-type. Patients with heterozygous UGT1A1 variants (i.e. *1/*28 or *1/*6) are eligible and should be counseled accordingly and be very closely monitored if randomized to the sacituzumab govitecan arm
- NOTE: If a patient's UGT1A1 status is unknown, they are eligible to enroll (the study does not require this test as part of screening)
- Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months of randomization are eligible
- For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated
- Patients with history of hepatitis C virus (HCV) infection must have been treated and considered cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load
- Patients with treated brain metastases are eligible if follow-up brain imaging after central nervous system (CNS)-directed therapy shows no evidence of progression and are not using steroids > 10 mg of prednisone (or equivalent) daily for brain metastases for at least 7 days prior to randomization
- Patients with prior or concurrent malignancy that is not considered clinically significant and whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen (at the discretion of the treating physician) are eligible
- Patient must not be on systemic immunosuppressive medication, including steroids (if doses exceed the equivalent of prednisone 10 mg daily). Short courses of steroids, e.g. "burst", which are discontinued prior to randomization are acceptable. Patients on inhaled, intranasal, intra-articular and/or topical steroids are eligible
- Patient must be English or Spanish speaking to be eligible for the HRQOL component of the study.
- NOTE: Sites cannot translate the associated HRQOL forms
Életkor a regiszterben: 18 év – - · Nem: nők és férfiak · Egészséges önkénteseket nem fogad
Helyszínek (163)
Helyszínek a regiszter sorrendjében. Ha a profilodba mented a városodat, távolság szerint rendeződnek.
| Helyszín | Város | Ország | Helyszín állapota |
|---|---|---|---|
| Avera Cancer Institute-Aberdeen | Aberdeen | Egyesült Államok | Toboroz |
| McFarland Clinic - Ames | Ames | Egyesült Államok | Toboroz |
| Mary Greeley Medical Center | Ames | Egyesült Államok | Toboroz |
| Community Hospital of Anaconda | Anaconda | Egyesült Államok | Toboroz |
| ThedaCare Regional Cancer Center | Appleton | Egyesült Államok | Toboroz |
| Duluth Clinic Ashland | Ashland | Egyesült Államok | Toboroz |
| Emory Saint Joseph's Hospital | Atlanta | Egyesült Államok | Toboroz |
| Emory University Hospital Midtown | Atlanta | Egyesült Államok | Toboroz |
| Emory University Hospital/Winship Cancer Institute | Atlanta | Egyesült Államok | Toboroz |
| Louisiana Hematology Oncology Associates LLC | Baton Rouge | Egyesült Államok | Toboroz |
| Houston Methodist San Jacinto Hospital | Baytown | Egyesült Államok | Toboroz |
| FHCC Overlake | Bellevue | Egyesült Államok | Toboroz |
| Central Vermont Medical Center/National Life Cancer Treatment | Berlin Corners | Egyesült Államok | Toboroz |
| Billings Clinic Cancer Center | Billings | Egyesült Államok | Toboroz |
| McFarland Clinic - Boone | Boone | Egyesült Államok | Felfüggesztve |
| Bozeman Health Deaconess Hospital | Bozeman | Egyesült Államok | Toboroz |
| Essentia Health Saint Joseph's Medical Center | Brainerd | Egyesült Államok | Toboroz |
| Trinity Health IHA Medical Group Hematology Oncology - Brighton | Brighton | Egyesült Államok | Toboroz |
| Roswell Park Cancer Institute | Buffalo | Egyesült Államok | Toboroz |
| University of Vermont and State Agricultural College | Burlington | Egyesült Államok | Toboroz |
| University of Vermont Medical Center | Burlington | Egyesült Államok | Toboroz |
| Trinity Health IHA Medical Group Hematology Oncology - Canton | Canton | Egyesült Államok | Toboroz |
| Saint Francis Medical Center | Cape Girardeau | Egyesült Államok | Toboroz |
| Mercy Hospital | Cedar Rapids | Egyesült Államok | Toboroz |
| Oncology Associates at Mercy Medical Center | Cedar Rapids | Egyesült Államok | Toboroz |
| Vandalia Health/CAMC Institute for Academic Medicine | Charleston | Egyesült Államok | Toboroz |
| Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital | Chelsea | Egyesült Államok | Toboroz |
| University of Illinois | Chicago | Egyesült Államok | Toboroz |
| Siteman Cancer Center at Saint Peters Hospital | City of Saint Peters | Egyesült Államok | Toboroz |
| Kootenai Health - Coeur d'Alene | Coeur d'Alene | Egyesült Államok | Toboroz |
| Ohio State University Comprehensive Cancer Center | Columbus | Egyesült Államok | Toboroz |
| Mercy Hospital | Coon Rapids | Egyesült Államok | Toboroz |
| Siteman Cancer Center at West County Hospital | Creve Coeur | Egyesült Államok | Toboroz |
| Houston Methodist Cypress Hospital | Cypress | Egyesült Államok | Toboroz |
| UT Southwestern/Simmons Cancer Center-Dallas | Dallas | Egyesült Államok | Toboroz |
| UT Southwestern Simmons Cancer Center - RedBird | Dallas | Egyesült Államok | Toboroz |
| Parkland Memorial Hospital | Dallas | Egyesült Államok | Toboroz |
| Geisinger Medical Center | Danville | Egyesült Államok | Toboroz |
| Carle at The Riverfront | Danville | Egyesült Államok | Toboroz |
| Decatur Memorial Hospital | Decatur | Egyesült Államok | Toboroz |
| Cancer Care Specialists of Illinois - Decatur | Decatur | Egyesült Államok | Toboroz |
| Essentia Health - Deer River Clinic | Deer River | Egyesült Államok | Toboroz |
| Geisinger Cancer Center Dickson City | Dickson City | Egyesült Államok | Toboroz |
| Essentia Health Cancer Center | Duluth | Egyesült Államok | Toboroz |
| Minnesota Oncology - Edina | Edina | Egyesült Államok | Toboroz |
| Fairview Southdale Hospital | Edina | Egyesült Államok | Toboroz |
| Crossroads Cancer Center | Effingham | Egyesült Államok | Toboroz |
| Carle Physician Group-Effingham | Effingham | Egyesült Államok | Toboroz |
| UPMC Hillman Cancer Center Erie | Erie | Egyesült Államok | Toboroz |
| Saint Vincent Hospital | Erie | Egyesült Államok | Toboroz |
| Essentia Health Cancer Center-South University Clinic | Fargo | Egyesült Államok | Toboroz |
| Parkland Health Center - Farmington | Farmington | Egyesült Államok | Toboroz |
| McFarland Clinic - Trinity Cancer Center | Fort Dodge | Egyesült Államok | Toboroz |
| UT Southwestern/Simmons Cancer Center-Fort Worth | Fort Worth | Egyesült Államok | Toboroz |
| Hematology Oncology Associates of Fredericksburg Inc | Fredericksburg | Egyesült Államok | Toboroz |
| UF Health Cancer Institute - Gainesville | Gainesville | Egyesült Államok | Toboroz |
| Benefis Sletten Cancer Institute | Great Falls | Egyesült Államok | Toboroz |
| UPMC Cancer Centers - Arnold Palmer Pavilion | Greensburg | Egyesült Államok | Toboroz |
| UPMC Pinnacle Cancer Center/Community Osteopathic Campus | Harrisburg | Egyesült Államok | Toboroz |
| HaysMed | Hays | Egyesült Államok | Toboroz |
| Margaret R Pardee Memorial Hospital | Hendersonville | Egyesült Államok | Toboroz |
| Penn State Milton S. Hershey Medical Center | Hershey | Egyesült Államok | Toboroz |
| Essentia Health Hibbing Clinic | Hibbing | Egyesült Államok | Toboroz |
| Methodist Willowbrook Hospital | Houston | Egyesült Államok | Toboroz |
| Houston Methodist West Hospital | Houston | Egyesült Államok | Toboroz |
| Houston Methodist Hospital | Houston | Egyesült Államok | Toboroz |
| IRMC Cancer Center | Indiana | Egyesült Államok | Toboroz |
| UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care | Irvine | Egyesült Államok | Toboroz |
| McFarland Clinic - Jefferson | Jefferson | Egyesült Államok | Felfüggesztve |
| Jefferson Hospital | Jefferson Hills | Egyesült Államok | Toboroz |
| Logan Health Medical Center | Kalispell | Egyesült Államok | Toboroz |
| University of Kansas Cancer Center - North | Kansas City | Egyesült Államok | Toboroz |
| University Health Truman Medical Center | Kansas City | Egyesült Államok | Toboroz |
| University of Kansas Cancer Center - Briarcliff | Kansas City | Egyesült Államok | Toboroz |
| University of Kansas Cancer Center | Kansas City | Egyesült Államok | Toboroz |
| FHCC at EvergreenHealth | Kirkland | Egyesült Államok | Toboroz |
| Gundersen Lutheran Medical Center | La Crosse | Egyesült Államok | Toboroz |
| University of Michigan Health - Sparrow Lansing | Lansing | Egyesült Államok | Toboroz |
| Lawrence Memorial Hospital | Lawrence | Egyesült Államok | Toboroz |
| Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center | Lebanon | Egyesült Államok | Toboroz |
| University of Kansas Cancer Center - Lee's Summit | Lee's Summit | Egyesült Államok | Toboroz |
| Geisinger Medical Oncology-Lewisburg | Lewisburg | Egyesült Államok | Toboroz |
| Cooperman Barnabas Medical Center | Livingston | Egyesült Államok | Toboroz |
| Trinity Health Saint Mary Mercy Livonia Hospital | Livonia | Egyesült Államok | Toboroz |
| Monmouth Medical Center | Long Branch | Egyesült Államok | Toboroz |
| UofL Health Medical Center Northeast | Louisville | Egyesült Államok | Toboroz |
| The James Graham Brown Cancer Center at University of Louisville | Louisville | Egyesült Államok | Toboroz |
| Avera Cancer Institute at Marshall | Marshall | Egyesült Államok | Toboroz |
| McFarland Clinic - Marshalltown | Marshalltown | Egyesült Államok | Toboroz |
| Carle Physician Group-Mattoon/Charleston | Mattoon | Egyesült Államok | Toboroz |
| UPMC Hillman Cancer Center at Rocco And Nancy Ortenzio Cancer Pavilion | Mechanicsburg | Egyesült Államok | Toboroz |
| Mary Bird Perkins Cancer Center - Metairie | Metairie | Egyesült Államok | Toboroz |
| Abbott-Northwestern Hospital | Minneapolis | Egyesült Államok | Toboroz |
| Community Medical Center | Missoula | Egyesült Államok | Toboroz |
| Avera Cancer Institute - Mitchell | Mitchell | Egyesült Államok | Toboroz |
| UPMC Hillman Cancer Center - Monroeville | Monroeville | Egyesült Államok | Toboroz |
| Forbes Hospital | Monroeville | Egyesült Államok | Toboroz |
| Houston Methodist Saint John Hospital | Nassau Bay | Egyesült Államok | Toboroz |
| Allegheny Valley Hospital | Natrona Heights | Egyesült Államok | Toboroz |
| Rutgers New Jersey Medical School | Newark | Egyesült Államok | Toboroz |
| Rutgers Cancer Institute of New Jersey | New Brunswick | Egyesült Államok | Toboroz |
| Cancer Center of Western Wisconsin | New Richmond | Egyesült Államok | Toboroz |
| Carle BroMenn Medical Center | Normal | Egyesült Államok | Toboroz |
| Carle Cancer Institute Normal | Normal | Egyesült Államok | Toboroz |
| HSHS Saint Elizabeth's Hospital | O'Fallon | Egyesült Államok | Toboroz |
| Cancer Care Center of O'Fallon | O'Fallon | Egyesült Államok | Toboroz |
| University of Oklahoma Health Sciences Center | Oklahoma City | Egyesült Államok | Toboroz |
| The University of Kansas Cancer Center - Olathe | Olathe | Egyesült Államok | Toboroz |
| UC Irvine Health- Chao Family Comprehensive Cancer Center | Orange | Egyesült Államok | Toboroz |
| University of Kansas Cancer Center-Overland Park | Overland Park | Egyesült Államok | Toboroz |
| Cancer Center at Saint Joseph's | Phoenix | Egyesült Államok | Toboroz |
| Avera Cancer Institute at Pierre | Pierre | Egyesült Államok | Toboroz |
| UPMC Hillman Cancer Center | Pittsburgh | Egyesült Államok | Toboroz |
| Allegheny General Hospital | Pittsburgh | Egyesült Államok | Toboroz |
| UPMC-Saint Margaret | Pittsburgh | Egyesült Államok | Toboroz |
| West Penn Hospital | Pittsburgh | Egyesült Államok | Toboroz |
| UPMC-Passavant Hospital | Pittsburgh | Egyesült Államok | Toboroz |
| Trinity Health Saint Joseph Mercy Oakland Hospital | Pontiac | Egyesült Államok | Toboroz |
| Kootenai Clinic Cancer Services - Post Falls | Post Falls | Egyesült Államok | Toboroz |
| UT Southwestern Clinical Center at Richardson/Plano | Richardson | Egyesült Államok | Toboroz |
| Virginia Cancer Institute | Richmond | Egyesült Államok | Toboroz |
| VCU Massey Cancer Center at Stony Point | Richmond | Egyesült Államok | Toboroz |
| VCU Massey Comprehensive Cancer Center | Richmond | Egyesült Államok | Toboroz |
| Sainte Genevieve County Memorial Hospital | Sainte Genevieve | Egyesült Államok | Toboroz |
| Dartmouth Cancer Center - North | Saint Johnsbury | Egyesült Államok | Toboroz |
| Park Nicollet Clinic - Saint Louis Park | Saint Louis Park | Egyesült Államok | Toboroz |
| United Hospital | Saint Paul | Egyesült Államok | Toboroz |
| Regions Hospital | Saint Paul | Egyesült Államok | Toboroz |
| Salina Regional Health Center | Salina | Egyesült Államok | Toboroz |
| Kootenai Clinic Cancer Services - Sandpoint | Sandpoint | Egyesült Államok | Toboroz |
| Essentia Health Sandstone | Sandstone | Egyesült Államok | Toboroz |
| University of Washington Medical Center - Montlake | Seattle | Egyesült Államok | Toboroz |
| FHCC at Northwest Hospital | Seattle | Egyesült Államok | Toboroz |
| Fred Hutchinson Cancer Center | Seattle | Egyesült Államok | Toboroz |
| UPMC Cancer Center at UPMC Northwest | Seneca | Egyesült Államok | Toboroz |
| Memorial Hospital East | Shiloh | Egyesült Államok | Toboroz |
| Avera Cancer Institute | Sioux Falls | Egyesült Államok | Toboroz |
| Robert Wood Johnson University Hospital Somerset | Somerville | Egyesült Államok | Toboroz |
| Springfield Clinic | Springfield | Egyesült Államok | Toboroz |
| Southern Illinois University School of Medicine | Springfield | Egyesült Államok | Toboroz |
| Springfield Memorial Hospital | Springfield | Egyesült Államok | Toboroz |
| Washington University School of Medicine | St Louis | Egyesült Államok | Toboroz |
| Siteman Cancer Center-South County | St Louis | Egyesült Államok | Toboroz |
| Siteman Cancer Center at Christian Hospital | St Louis | Egyesült Államok | Toboroz |
| Missouri Baptist Medical Center | St Louis | Egyesült Államok | Toboroz |
| Stony Brook University Medical Center | Stony Brook | Egyesült Államok | Toboroz |
| Houston Methodist Sugar Land Hospital | Sugar Land | Egyesült Államok | Toboroz |
| Missouri Baptist Sullivan Hospital | Sullivan | Egyesült Államok | Toboroz |
| Houston Methodist The Woodlands Hospital | The Woodlands | Egyesült Államok | Toboroz |
| Community Medical Center | Toms River | Egyesült Államok | Toboroz |
| University of Kansas Health System Saint Francis Campus | Topeka | Egyesült Államok | Toboroz |
| UPMC Cancer Center-Uniontown | Uniontown | Egyesült Államok | Toboroz |
| Carle Cancer Center | Urbana | Egyesült Államok | Toboroz |
| Essentia Health Virginia Clinic | Virginia | Egyesült Államok | Toboroz |
| UPMC Cancer Center-Washington | Washington | Egyesült Államok | Toboroz |
| Reading Hospital | West Reading | Egyesült Államok | Toboroz |
| University of Kansas Hospital-Westwood Cancer Center | Westwood | Egyesült Államok | Toboroz |
| Wexford Health and Wellness Pavilion | Wexford | Egyesült Államok | Toboroz |
| Geisinger Wyoming Valley/Henry Cancer Center | Wilkes-Barre | Egyesült Államok | Toboroz |
| Roswell Park Amherst Center | Williamsville | Egyesült Államok | Toboroz |
| UMass Memorial Medical Center - University Campus | Worcester | Egyesült Államok | Toboroz |
| Avera Cancer Institute at Yankton | Yankton | Egyesült Államok | Toboroz |
| Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus | Ypsilanti | Egyesült Államok | Toboroz |
Ez az oldal tájékoztatás, nem orvosi tanács. Bármely vizsgálatról az orvosoddal beszélj.